CorMedix is a bio-pharmaceutical company that produces DefenCath, an antimicrobial catheter lock solution containing ...

CRBSI can be diagnosed when colony counts are at least 3-fold higher in cultures of blood obtained via the CVC than in cultures of blood taken from a peripheral vein. [6] ...

Patricia M. Flynn, MD, MS Disclosures Pediatr Infect Dis J. 2009;28 (11):1016-1017.

Catheter-related bloodstream infection (CRBSI) or central line-associated bloodstream infections (CLABSIs) are associated with increased morbidity, mortality and healthcare costs. 1 The epidemiology ...

The global CRBSI Treatment Market is projected to be valued at USD 1,718.0 Million in 2025 and is expected to reach USD 2,908 Million by 2035, registering a CAGR of 5.4% during the forecast period, ...